An error occurred on this page.
These results could be incomplete or invalid. Staff have been notified.



Studies associated with ontology term
MP:0005376   'homeostasis/metabolism phenotype'    
Navigate ontologies  


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackerman1 study archive
with methacholine 		Lung, respiratory function, baseline and methacholine-challenged (several doses). QTL population f 7-8wks 2005
Albers1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet 		Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Attie2 metabolic panel
with high-fat high-sucrose diet 		Glucose, HOMA-IR, HOMA-B. DO population both 4-26wks 2018
Attie2 hormone quantification
with high-fat high-sucrose diet 		Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. DO population both 4-26wks 2018
Attie2 lipid profile
with high-fat high-sucrose diet 		Triglyceride. DO population both 4-26wks 2018
Attie2 glucose tolerance
with high-fat high-sucrose diet 		Area under curve. DO population both 4-26wks 2018
Auwerx1 monitoring system
with high-fat diet 		Oxygen consumption and respiratory exchange ratio (RER); activity. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 glucose tolerance
with high-fat diet 		Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 hormone quantification
with high-fat diet 		Glucose post oral gavage: 0, 15, 30 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 body temperature
with high-fat diet 		In cold room: 0, 1, 2, 3, 4, 5, 6 h. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 treadmill endurance test
with high-fat diet 		Distance traveled. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 running wheel monitoring
with high-fat diet 		Distance traveled, speed. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 metabolic panel
with high-fat diet 		Enzymes, bile acid, proteins, creatinine, glucose, iron, lactate. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 lipid profile
with high-fat diet 		Cholesterol, HDL, LDL, free fatty acids, triglyceride. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 cell signaling molecule detection
with high-fat diet 		INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. BXD w/par   (57) m 8-29 wks 2016
Auwerx2 monitoring system
with high-fat diet 		Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. inbred w/CC8 both 8-21 wks 2021
Auwerx2 glucose tolerance
with high-fat diet 		Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. inbred w/CC8 both 8-21 wks 2021
Auwerx2 hormone quantification
with high-fat diet 		Insulin levels following glucose post oral gavage: 0, 15, 30 min. inbred w/CC8 both 8-21 wks 2021
Auwerx2 treadmill endurance test
with high-fat diet 		Distance traveled. inbred w/CC8 both 8-21 wks 2021
Auwerx2 metabolic panel
with high-fat diet 		Enzymes, creatinine, iron, lactate, urea. inbred w/CC8 both 8-21 wks 2021
Auwerx2 lipid profile
with high-fat diet 		Cholesterol, HDL, LDL, triglycerides, free fatty acids. inbred w/CC8 both 8-21 wks 2021
Bautz1 study archive Plasma lipids. Cholesterol, triglycerides. QTL population both 12-14wks 2013
Beamer2 study archive Bone morphology and strength, insulin-like growth factor 1. QTL population f 16wks 2001
Bennett3 alcohol quantification
with ethanol 		Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. ILSXISS w/par   (74) both 8-14wks 2007
Bennett4 metabolic panel Plasma enzymes, creatinine, glucose, urea, metabolic health score. both 8-20wks 2021
Bennett4 lipid profile Cholesterol, non-esterified fatty acids, triglyceride. both 8-20wks 2021
Bennett4 biomarker quantification TMAO, choline, phosphocholine, glycerophosphocholine, betaine, carnitine. both 8-20wks 2021
Bennett4 hormone quantification Insulin, glucose:insulin ratio. both 8-20wks 2021
Bennett4 monitoring system O2 consumption, CO2 production, RER, heat expenditure, activity. both 8-20wks 2021
Bennett4 intake monitoring Food intake; energy intake; protein, carbohydrate, fat intake. both 8-20wks 2021
Berndt1 ventilator
with methacholine 		Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine 		Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine 		Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt3 metabolite quantification Vitamin D concentration (serum). inbred   (18) m 11wks 2011
Brockmann1 study archive Body, organ weights, litter size, abdominal fat, lipids, insulin, leptin. QTL population both 3-6wks 2009
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. inbred   (10) both 8wks 2013
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno3 metabolic panel Glucose (plasma). 4h fast. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. CC diallel w/par   (62) both 8-16wks 2012
Chesler2 metabolic panel Clinical blood chemistry. 16h fast. CC diallel w/par   (62) both 7-15wks 2011
Chesler3 metabolic panel Clinical blood chemistry. 16h fast. CC pre w/par   (367) both 7-15wks 2011
Chesler6 study archive
with ethanol 		Sensitivity to ethanol. Baseline and ethanol. QTL population both 9-34wks 2012
Cheverud1 glucose tolerance
with high-fat diet 		High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 lipid profile
with high-fat diet 		Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 hormone quantification
with high-fat diet 		Insulin, leptin. LGXSM w/par   (19) both 12-16wks 2004
Clemens1 study archive
with ultraviolet light 		Immunosuppression of contact hypersensitivity after ultraviolet light exposure QTL population both 9-30wks 2000
Cowell1 hormone quantification
with Staphylococcus aureus 		Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. inbred   (13) f 8wks 2012
Crabbe2 drug and metabolite quantification
with diazepam 		Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. inbred   (15) both 6-7wks 1998
Crabbe2 body temperature
with diazepam 		Baseline vs. 30 min after diazepam injection (several doses). inbred   (15) both 6-7wks 1998
Crabbe4 alcohol quantification
with ethanol 		Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crowley1 body weight
with haloperidol 		Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol 		Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
DiPetrillo2 urinalysis Microalbumin, creatinine, ratio. CC pre w/par   (163) m 10wks 2012
Donahue1 metabolic panel Thyroxine (serum). inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. inbred w/CC7   (30) both 15-16wks 2002
Donahue9 metabolic panel Clinical blood chemistry (serum). 4h fast. B6.PWD consomic w/par   (25) both 11wks 2011
Doorenbos1 study archive Urinalysis. Creatinine, microalbumin, body weight. QTL population m 8-10wks 2008
Eumorphia1 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. inbred   (8) both 12wks 2007
Eumorphia1 metabolic panel Clinical blood chemistry (plasma). Unknown fast. inbred   (8) both 12wks 2007
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. inbred   (4) both 12, 24, 52 wks 2008
Eumorphia5 body temperature Hourly readings in cold room. 6h test. inbred   (4) both 12wks 2008
Farmer1 study archive Colitis susceptibility, severity. Colon histopathology, body and spleen weight. QTL population both 6wks 2001
Frankel1 electroconvulsion test
with lamotrigine 		Electroconvulsive thresholds. Lamotrigine. 2 test sites. inbred   (16) both 6-11wks 2000
GMC06 metabolic panel Glucose, glycerol. 16h fast. inbred   (5) both 10-11wks 2020
GMC06 lipid profile Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. inbred   (5) both 10-11wks 2020
GMC09 monitoring system Locomotor activity and energy metabolism. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC11 glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. inbred w/CC8   (6) both 13-14wks 2020
GMC16 metabolic panel Clinical blood chemistry (plasma). No fast. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC16 lipid profile Cholesterol, triglycerides. No fast, plasma. inbred w/CC8   (8) both 16-17, 20-21wks 2020
Gould1 drug and metabolite quantification
with lithium 		Lithium concentration in brain tissue and blood serum after lithium (several doses). inbred   (11) m 7-8wks 2011
Gould2 drug and metabolite quantification
with nicotine 		Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. inbred   (8) m 8-12wks 2011
Graham1 RNA expression profiling
with West Nile virus 		Viral load and expression of Ifnb1 and Ifit1 in brain, kidney and spleen. CC RIX   (5) m 8-10wks 2015
Graham3 immune cell quantification Baseline splenic T cell subsets. CC RIX   (104) m 8-10wks 2021
Graubert1 histopathology
with ENU 		Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. inbred   (20) both 9wks; 12-64wks 2006
Gros1 genotype assessment
with Candida albicans 		C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Hadsell2 mineral quantification concentrations of various minerals in milk inbred   (31) f 14-20wks 2018
Hageman1 study archive eQTL, urinary albumin excretion using microarray. QTL population m 8-10wks 2011
Harrill1 organ weights
with isoniazid 		Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 body weight
with isoniazid 		Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid 		Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid 		Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid 		Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 body weight
with DB289 		DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289 		Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289 		Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 biomarker quantification
with DB289 		Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289 		Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289 		Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Haston1 health assessment
with radiation 		Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation 		Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation 		Post exposure to radiation. inbred   (26) both 15-36wks 2012
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
Ishimori1 study archive
with high-fat diet 		Lipids, atherosclerosis lesions, parathyroid hormone after high-fat diet. QTL population f 20wks 2004
JaxCC1 urinalysis Microalbumin, creatinine, ratio. CC   (18) both various 2018
JaxCC1 metabolic panel Clinical blood chemistry (plasma). No fast. CC   (18) both various 2018
JaxCC1 lipid profile Cholesterol, HDL, triglycerides, fatty acids. No fast, plasma. CC   (18) both various 2018
JaxCC1 hormone quantification Insulin (plasma). CC   (18) both various 2018
JaxKOMP-EAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 8-18wks 2021
JaxKOMP-EAP urinalysis Microalbumin, creatinine, ratio. KOMP both 8-18wks 2021
JaxKOMP-EAP lipid profile Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. KOMP both 8-18wks 2021
JaxKOMP-EAP metabolic panel Clinical blood chemistry (plasma). No fast. KOMP both 8-18wks 2021
JaxKOMP-EAP hormone quantification Insulin (plasma). KOMP both 8-18wks 2021
JaxKOMP-LAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 66-81wks 2021
JaxKOMP-LAP metabolic panel Clinical blood chemistry (plasma). No fast. KOMP both 66-81wks 2021
Jaxpheno3 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred   (11) both 8, 16 wks 2006
Jaxpheno3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred   (11) both 8, 16 wks 2006
Karst1 study archive Characterization of high-muscle-mass mice. QTL population both 3-10wks 2011
Kim1 study archive Glucose, insulin, body and fat pad weights. QTL population m 20-26wks 2001
Klaassen1 histopathology
with cadmium 		Cadmium-induced toxicity to liver, testis, trigeminal ganglia. inbred   (8) m 8wks 2001
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Lake1 metabolic panel Glucose, bilirubin, aspartate transaminase (plasma). 4h fast. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 lipid profile Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. B6.A consomic w/par   (23) both 7-11wks 2005
Leiter2 study archive Type 1 diabetes development study. QTL population f 14-40wks 2009
Li1 study archive
with western diet 		Lipids, atherosclerosis lesion histopathology. High-fat, western-style diet. QTL population f 12wks 2008
Lightfoot1 running wheel monitoring Distance, duration, speed. inbred   (41) both 8-9wks 2010
Lionikas1 body weight
with exercise 		Exercise (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 microscopy
with exercise 		Muscle fibers. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 muscle weights
with exercise 		Various muscles. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 organ weights
with exercise 		Heart weight. Cardiac ventricle weight. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 bone dimensions
with exercise 		Femur length. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 swim endurance test
with exercise 		Exercise vs. control, weekly for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 protein activity assessment
with exercise 		Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lyons1 study archive
with high-fat diet 		Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population m 16-18wks 2003
Lyons2 study archive
with high-fat diet 		Lipids (plasma), bile, liver weight, gallbladder and gallstone histopathology. QTL population m 16-18wks 2003
Lyons3 study archive
with high-fat diet 		Lipids, gallbladder and gallstone histopathology after high-fat diet. QTL population m 14-20wks 2004
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Mathes1 body weight
with exercise 		Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 MRI
with exercise 		Body composition (percent fat). Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 intake monitoring
with exercise 		Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. CC pre w/par   (184) m 10-12wks 2011
Mathes1 running wheel monitoring
with exercise 		Distance, speed at days 1, 6, and 12. CC pre w/par   (184) m 10-12wks 2011
Mathews1 study archive Type 1 diabetes resistance. QTL population f 8-40wks 2003
Maurer1 body weight
with atenolol, isoproterenol 		Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol 		Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol 		Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol 		Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
McMullan1 treadmill endurance test Maximal distance is recorded when mouse fails to run. CC   (50) f 17-72wks 2017
McMullan2 running wheel monitoring Running wheel activity each day for 28 days. CC   (43) f 5-22wks 2017
McMullan7 monitoring system
with exercise 		Locomotor activity, respiratory activity, body heat production, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. CC   (4) both 8-10wks 2018
Mooney1 protein activity assessment Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus inbred   (20) m 8-12wks 2021
Nadeau2 metabolic panel
with high-fat high-sucrose diet 		Glucose, insulin, insulin resistance after 16wks of high-fat high-sucrose diet. 16h fast. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau2 lipid profile
with high-fat high-sucrose diet 		Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau3 hormone quantification
with high-fat high-sucrose diet 		Insulin and insulin resistance after 16 wks of high-fat high-sucrose diet. Overnight fast. inbred   (2) m 21 wks 2016
Nadeau3 lipid profile
with high-fat high-sucrose diet 		Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. inbred   (2) m 21 wks 2016
Naggert1 metabolic panel
with high-fat diet 		Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet 		Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Neuner1 biomarker quantification Temporal cortex amyloid level, age 6 and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Paigen1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen2 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen3 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen3 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. obesity mutants   (8) both 15-19wks 2000
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Palmer3 metabolic panel Glucose (blood). Before and after 16h fast. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 metabolic panel Glucose (blood). Before and after 16h fast. F1 Tcf7l2   (30) both 7-14wks 2017
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Pitman1 study archive
with high-fat diet 		Cholesterol (plasma) after high-fat diet (several timepoints). QTL population f 6-26wks 2002
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Reifsnyder1 study archive Body weight (several ages), fat mass, body mass index, fat pad weights. QTL population m 4-24wks 2000
Reifsnyder2 study archive Type 1 diabetes onset. QTL population f 12-40wks 2005
Rhodes1 running wheel monitoring
with exercise 		Locomotor activity. Exercise wheel group vs. control group. Distance per day. inbred   (12) both 8-15wks 2010
Rhodes1 body weight
with exercise 		Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rhodes1 microscopy
with exercise 		Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rice1 proteomic profiling Hair proteomics analysis. Spectral counts for 46 specific proteins. inbred   (11) both 10-19wks 2012
Richards-Smith1 study archive
with macronutrient diet option 		Caloric intake, glucose, body and fat pad weights. Macronutrient diet option. QTL population m 8-13wks 2002
Richfield1 neurotransmitter quantification Neurotransmitters. Molecular measures. inbred   (15) m 7-9wks 2003
RIKEN-EAD1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred RBRC   (56) both 8, 12 wks 2008
RIKEN-EAD1 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. inbred RBRC   (56) both 8, 12 wks 2008
RIKEN-EAD2 metabolic panel Clinical blood chemistry (plasma). 4h fast. wild-derived RBRC   (33) both 8, 12 wks 2008
RIKEN-EAD2 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. wild-derived RBRC   (33) both 8, 12 wks 2008
Rusyn2 metabolic panel
with trichloroethylene 		Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. inbred   (17) m 7wks 2010
Rusyn2 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. inbred   (17) m 7wks 2010
Rusyn5 metabolic panel
with high-fat diet and ethanol 		Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 alcohol quantification
with high-fat diet and ethanol 		Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 metabolite quantification
with high-fat diet and ethanol 		Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 lipid profile
with high-fat diet and ethanol 		Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn6 organ weights
with trichloroethylene 		Liver, kidney weights. Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 metabolic panel
with trichloroethylene 		Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. inbred   (7) m 6-7wks 2014
Rusyn6 RNA expression profiling
with trichloroethylene 		Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. inbred   (7) m 6-7wks 2014
Rusyn6 histopathology
with trichloroethylene 		Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. inbred   (7) m 6-7wks 2014
Sandell1 health assessment Post-injury wound healing. Ear cartilage and articular cartilage. LGXSM w/par   (15) both 6-7wks 2012
Sandell1 histopathology Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. LGXSM w/par   (15) both 6-7wks 2012
Schoenrock1 body temperature
with various diets 		Temperature before and after stress. Comparison of 4 diets. CC RIX   (18) f 8-9 wks 2018
Schoenrock1 hormone quantification
with various diets 		Serum corticosterone at baseline and 10 mins after stress. Comparison of 4 diets. CC RIX   (18) f 8-9 wks 2018
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 lipid profile Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. inbred   (11) both 8-10wks 2005
Schonfeld1 metabolic panel Glucose, beta-hydroxybutyrate (plasma). No fast. inbred   (11) both 8-10wks 2005
Schonfeld1 hormone quantification Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. inbred   (11) both 8-10wks 2005
Schoonjans1 glucose tolerance
with high-fat diet 		Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. BXD w/par   (36) m 8-29 wks 2022
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin 		Lung inflammatory changes. Ovalbumin vs. control. inbred   (8) m 6-8wks 2001
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. inbred   (16) both 7-9wks 2001
Sheehan1 study archive Urinalysis. Creatinine, microalbumin, body weight. QTL population m 10wks 2007
Shockley1 lipid profile
with high-fat diet 		Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. inbred   (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet 		Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. inbred   (10) both 10-13wks 2008
Solberg1 study archive Open field test, forced swim test, defensive burying task. QTL population both 11-17wks 2004
Stylianou2 study archive Lipids. Cholesterol, triglycerides, body weight. QTL population both 8-10wks 2006
Su2 study archive
with high-fat diet 		Lipids (plasma). Cholesterol, triglycerides, aortic lesions, body mass index. QTL population f 14wks 2009
Sunde1 RNA expression profiling
with selenium 		Selenium regulation of selenoprotein enzyme activity and transcripts. inbred w/CC8   (8) m 3-14wks 2018
Svenson3 coagulation test Fibrinogen, anti-thrombin III, factor VIII B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 metabolic panel Glucose, bilirubin, blood urea nitrogen, aspartate transaminase (plasma). 4h fast. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson7 metabolic panel
with high-fat high-sucrose diet 		Clinical chemistry at 8 and 19 wks of age. 4h fast. Clinical chemistry at 17 wks of age. No fast. DO population both 3-30 wks 2020
Svenson7 lipid profile
with high-fat high-sucrose diet 		Cholesterol, fatty acids, triglyceride at 8 and 19 wks of age. 4h fast. DO population both 3-30 wks 2020
Svenson7 urinalysis
with high-fat high-sucrose diet 		Glucose, creatinine, microalbumin, albumin-creatinine ratio at 11 and 20 wks of age. DO population both 3-30 wks 2020
Svenson7 glucose tolerance
with high-fat high-sucrose diet 		0-180 min after 20% glucose i.p. at 23-24 wks of age. 15h fast. DO population both 3-30 wks 2020
Threadgill1 metabolic panel
with acetaminophen 		Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen 		Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen 		Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 biomarker quantification
with acetaminophen 		Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen 		Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill2 metabolic panel
with acetaminophen 		Alanine transaminase (serum). Acetaminophen (several doses) vs. control. inbred   (5) m 6-8wks 2005
Threadgill2 metabolite quantification
with acetaminophen 		Glutathione. inbred   (5) m 6-8wks 2005
Threadgill2 drug and metabolite quantification
with acetaminophen 		Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). inbred   (5) m 6-8wks 2005
Threadgill2 histopathology
with acetaminophen 		Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. inbred   (5) m 6-8wks 2005
Tomasini1 biomarker quantification Fibronectin. inbred   (25) both 9wks 2007
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Trullas1 hormone quantification Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). inbred   (16) m 6-8wks 1993
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). inbred   (18) both 8wks 2010
Wang1 study archive
with high-fat diet 		Lipids (plasma). Cholesterol, inducibility, triglycerides, atherosclerosis lesions. QTL population f 10-23wks 2003
Wiltshire2 drug and metabolite quantification
with fluoxetine 		Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine 		Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib 		In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Wittenburg2 study archive
with high-fat diet 		Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population both 6-16wks 2003
Wittenburg3 study archive
with high-fat diet 		Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population both 2005
Xenakis1 inclined screen test Latency to move all four paws. CC RIX   (73) both 7-13wks 2020
Xenakis1 open field test Locomotor activity, anxiety, stereotypy. CC RIX   (73) both 7-13wks 2020
Xenakis1 behavior observation Vacuous chewing, tongue protrusion, jaw tremor. CC RIX   (73) both 7-13wks 2020
Xenakis1 drug and metabolite quantification Plasma haloperidol concentration. CC RIX   (73) both 7-13wks 2020
Xenakis2 body weight
with arsenic 		Baseline, then after iAs exposure for 26 wks DO population m 4-34 wks 2022
Xenakis2 intake monitoring
with arsenic 		Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure DO population m 4-34 wks 2022
Xenakis2 MRI
with arsenic 		Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure DO population m 4-34 wks 2022
Xenakis2 urinalysis
with arsenic 		Urine volume at baseline, and 12 and 24 wks after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolic panel
with arsenic 		Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 hormone quantification
with arsenic 		Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolite quantification
with arsenic 		iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) DO population m 4-34 wks 2022
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Zhang1 study archive
with western diet 		Atherosclerosis and glucose homeostasis. Lesions, lipids, glucose, insulin. High-fat, western-style diet. QTL population f <6-18wks 2012
Zimmermann1 monitoring system Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020